Flashpoint Therapeutics

About Flashpoint Therapeutics

Flashpoint Therapeutics is a clinical-stage biotechnology company focused on developing precision-engineered structural nanomedicines. Their platform enables targeted therapies that co-deliver optimized combinations of therapeutic components (like mRNA, DNA, proteins, and CRISPR) to individual cells, enhancing drug delivery, stability, potency, and safety. They aim to advance a robust pipeline of first-in-class nanomedicines through internal development and strategic partnerships.

Products & Services

Structural Nanomedicines:A platform for creating targeted therapies with optimized nanoscale architecture, delivering precise combinations of nucleic acids, peptides, and small molecules to over 60 cell types with enhanced potency, stability, and safety.

Cancer Immunotherapy:First-in-class candidates delivering immune stimulatory molecules with optimized activation kinetics to induce robust anti-tumor immune responses, showing curative outcomes in some studies.

Next-Gen Nucleic Acid and Peptide Nanotherapeutics:Modular platform for rapid development of novel therapies delivering DNA, RNA, peptides, CRISPR, and targeting moieties with improved delivery, potency, and safety profiles.

Specialties

Nanotechnology Structural Nanomedicines Cancer Immunotherapy Nucleic Acid Therapeutics Peptide Therapeutics CRISPR-based Therapies Drug Delivery Systems

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 10000000 MR: - FA: 10M FAN: 10000000	D: 2023-10-25 FD: 2023-10-25	2 investors

Seed Latest

2023-10-25

$10.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Barry Labinger

Chief Executive Officer

LinkedIn (Pro only)

E

Eric Rowinsky

Consulting Chief Medical Officer

LinkedIn (Pro only)

R

Raymond Nimrod

Legal, IP Strategy

M

Michael Evangelopoulos

BD Manager

A

Alex Anderson

Senior Scientist

J

Jasper Dittmar

Research Scientist

View 21 more team members with Pro

Unlock Full Team Directory

Recent News